JWH 161

JWH-161 is a cannabinoid derivative that was designed by Dr John W. Huffman's team as a hybrid between the dibenzopyran "classical" cannabinoid drugs and the novel indole derivatives, in an attempt to unravel the differences in their binding modes to the CB₁ receptor. While retaining structural elements from both families, JWH-161 has a CB₁ K_i of 19.0nM, although it was found to be slightly weaker than THC in animal tests.